Data / Form D filings / Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc.: Form D filings
Lyra Therapeutics, Inc., a biotechnology company in Watertown, MA, filed 13 Form D notices with the SEC between 2009 and 2023. The latest, on June 9, 2023, reports $50 million sold of a $50 million offering to 24 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 480 Arsenal Way, Watertown, MA, 02472
- Phone
- (617) 373-4600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1327273
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 9, 2023 | New notice | $50,000,008 | $50,000,008 | 24 | May 25, 2023 | sec.gov | |
| Apr 26, 2022 | New notice | $100,494,970 | $100,494,970 | 34 | Apr 12, 2022 | sec.gov | |
| Jan 27, 2020 | New notice | $28,049,999 | $28,049,999 | 14 | Jan 10, 2020 | sec.gov | |
| Nov 28, 2016 | New notice | $5,999,999 | $5,999,999 | 9 | Nov 10, 2016 | sec.gov | |
| Apr 12, 2013 | New notice | $21,213,551 | $17,956,999 | $3,256,552 | 11 | Mar 29, 2013 | sec.gov |
| Oct 30, 2012 | New notice | $6,000,000 | $5,078,139 | $921,861 | 10 | Oct 15, 2012 | sec.gov |
| Nov 8, 2011 | New notice | $3,000,000 | $3,000,000 | 1 | Oct 24, 2011 | sec.gov | |
| Sep 8, 2011 | New notice | $18,000,002 | $12,000,000 | $6,000,002 | 10 | Sep 7, 2011 | sec.gov |
| Aug 12, 2010 | New notice | $3,000,000 | $3,000,000 | 1 | Jul 30, 2010 | sec.gov | |
| May 18, 2010 | New notice | $10,051,308 | $10,051,308 | 11 | May 13, 2010 | sec.gov | |
| Mar 19, 2010 | New notice | $1,000,000 | $1,000,000 | 8 | Mar 19, 2010 | sec.gov | |
| Jan 20, 2010 | New notice | $2,050,000 | $2,050,000 | 9 | Jan 14, 2010 | sec.gov | |
| Apr 14, 2009 | New notice | $12,187,500 | $8,187,500 | $4,000,000 | 10 | Apr 3, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| W. Bradford Smith | Director | |
| Konstantin Ann Poukalov | Director | |
| Maria Palasis, Ph.D. | Executive Officer, Director | |
| James R. Tobin | Director | |
| Nancy Bradford Snyderman, M.D., FACS | Director | |
| C. Ann Merrifield | Director | |
| Richard R. Nieman, M.D. | Executive Officer | |
| Harlan Waksal, M.D. | Executive Officer, Director | |
| John R. Bishop, Ph.D. | Executive Officer | |
| Jason Cavalier | Executive Officer | |
| Michael Altman | Director | |
| Edward Anderson | Director |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Jun 5, 2023 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Lyra Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.